Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The company was founded in 2001 and is headquartered in Kunming, China.
Research context
Walvax Biotechnology Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Walvax Biotechnology Co., Ltd is currently in a long term uptrend where the price is trading 22.7% above its 200 day moving average.
From a valuation standpoint, the stock is 152.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 24.3.
Walvax Biotechnology Co., Ltd's total revenue rose by 323.9% to $1B since the same quarter in the previous year.
Its net income has increased by 2527.6% to $568M since the same quarter in the previous year.
Finally, its free cash flow fell by 15.2% to $-137M since the same quarter in the previous year.
Based on the above factors, Walvax Biotechnology Co., Ltd gets an overall score of 3/5.